Cytokinetics - CYTK Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CYTK shares.
View CYTK analyst ratings or view top-rated stocks.

10 equities research analysts have issued 12-month price targets for Cytokinetics' shares. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they anticipate the company's stock price to reach $61.73 in the next year. This suggests a possible upside of 25.4% from the stock's current price.
View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts.

Cytokinetics' stock was trading at $45.58 at the start of the year. Since then, CYTK stock has increased by 8.0% and is now trading at $49.23.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CYTK earnings forecast.

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its quarterly earnings data on Thursday, August, 4th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($1.04) by $0.81. The biopharmaceutical company earned $88.97 million during the quarter, compared to analyst estimates of $3.73 million. Cytokinetics had a negative trailing twelve-month return on equity of 118.37% and a negative net margin of 142.85%. The business's quarterly revenue was up 3029.4% on a year-over-year basis. During the same period last year, the firm earned ($0.86) EPS.

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (4.78%), Pictet Asset Management SA (2.58%), Lazard Asset Management LLC (1.98%), Driehaus Capital Management LLC (1.75%), Artal Group S.A. (1.35%) and Deerfield Management Company L.P. Series C (1.23%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Sandford D Smith, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends.

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYTK stock can currently be purchased for approximately $49.23.

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $4.63 billion and generates $70.43 million in revenue each year. The biopharmaceutical company earns $-215,310,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.

The company employs 253 workers across the globe.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.